$1.290
+0.031 (+2.38%)At close
INO News
INO Events
INOVIO Estimates Cash Balance Supports Operations into Late Q1 2027
INOVIO estimates that current cash, cash equivalents and short-term investments balances of $36.7M - excluding net proceeds from the July 2026 offering of approximately $18.3M - will support operations into late 1Q27, through a potential launch of INO-3107, if approved. "As the FDA's review of our BLA for INO-3107 continues to advance, we are pleased to have held the informal clinical meeting with the FDA, where we presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, and our rationale for accelerated approval eligibility," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We are confident in INO-3107's potential to become the preferred product among patients, healthcare providers and payers, if approved, and are committed to ensuring that all patients have access to therapeutic options that work for them in reducing the need for surgery to control their disease. We look forward to the final stages of the review process and further advancing our commercial preparations."
Faraday Future Borrow Rate Increases to 303.37%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Faraday Future Intelligent Electric Inc (FFAI) 303.37% +6.22, GraniteShares 2x Long INTC Daily ETF (INTW) 6.83% +1.88, American Resources Corp (AREC) 13.78% +1.49, Hertz Global Holdings (HTZ) 9.22% +1.44, Direxion Daily Semiconductor Bear 3X Shares (SOXS) 7.35% +1.39, ProShares UltraPro Short QQQ (SQQQ) 5.15% +1.34, Inovio (INO) 4.43% +0.77, ProShares Ultra DJ UBS Crude Oil (UCO) 12.97% +0.61, GraniteShares 1.5x Long COIN Daily ETF (CONL) 14.97% +0.58, and DEFIANCE DAILY TARGET 2X LONG SMCI ETF (SMCX) 11.72% +0.48.
Latest Data Shows JEPQ Borrow Rate Increases to 18.37%
Latest data shows the largest indicative borrow rate increases among liquid option names include: JEPQ (JEPQ) 18.37% +6.49, Merlin Inc (MRLN) 19.75% +1.05, Inovio (INO) 3.27% +0.83, United States Oil Fund (USO) 3.80% +0.59, Icici Bank (IBN) 3.26% +0.48, Columbia Financial (CLBK) 1.81% +0.39, Grayscale Ethereum Trust ETF (ETHE) 1.29% +0.29, GraniteShares 2x Long NOW Daily ETF (NOWL) 9.29% +0.29, GDS Holdings (ADS) (GDS) 1.76% +0.28, and Critical Metals Corp (CRML) 10.02% +0.27.
Inovio Files $300M Mixed Securities Shelf
Inovio files $300M mixed securities shelf
Inovio Partner ApolloBio Announces Positive Results for VGX-3100 Key Trial
Inovio announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from the study to support a future regulatory submission of VGX-3100 in China. "We believe these positive topline results for VGX-3100 reflect both the potential of our DNA medicine platform in HPV-related diseases and the power of partnerships to advance innovative DNA immunotherapies," said Dr. Jacqueline Shea, Inovio's President and CEO. "We look forward to these data being presented at upcoming international medical conferences and published in peer-reviewed publications. We also anticipate future updates from ApolloBio as they work towards filing for potential regulatory approval of VGX-3100 in China." According to the terms of the ApolloBio Agreement, INOVIO is entitled to receive up to an aggregate of $20M, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in specified territories. In the event that VGX-3100 is approved for marketing, INOVIO will be entitled to receive royalty payments based on a tiered percentage of annual net sales.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.